Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2014; 20(35): 12493-12500
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12493
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12493
Current treatment options for colon cancer peritoneal carcinomatosis
Tomoyoshi Aoyagi, Krista P Terracina, Ali Raza, Kazuaki Takabe, Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0011, United States
Author contributions: All the authors generated the ideas and contributed to the writing of this paper.
Supported by NIH grants, No. R01CA160688 (to Takabe K) and No. T32CA085159-10 (to Terracina KP)
Correspondence to: Kazuaki Takabe, MD, PhD, FACS, Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine, West Hospital 7-402, 1200 East Broad Street, Richmond, VA 23298-0011, United States. ktakabe@vcu.edu
Telephone: +1-804-8289322 Fax: +1-804-8284808
Received: February 10, 2014
Revised: April 10, 2014
Accepted: June 2, 2014
Published online: September 21, 2014
Processing time: 221 Days and 19 Hours
Revised: April 10, 2014
Accepted: June 2, 2014
Published online: September 21, 2014
Processing time: 221 Days and 19 Hours
Core Tip
Core tip: This paper aims to review the clinical presentation, the mechanisms of disease progression, and current treatment options for colon cancer peritoneal carcinomatosis, with a focus on the benefits and limitations of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.